کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2116306 | 1084825 | 2013 | 8 صفحه PDF | دانلود رایگان |
Intracellular-acting peptide drugs are effective for inhibiting cytoplasmic protein targets, yet face challenges with penetrating the cancer cell membrane. We have developed a lipid nanoparticle formulation that utilizes a pH-sensitive calcium carbonate complexation mechanism to enable the targeted delivery of the intracellular-acting therapeutic peptide EEEEpYFELV (EV) into lung cancer cells. Lipid–calcium-carbonate (LCC) nanoparticles were conjugated with anisamide, a targeting ligand for the sigma receptor which is expressed on lung cancer cells. LCC EV nanoparticle treatment provoked severe apoptotic effects in H460 non-small cell lung cancer cells in vitro. LCC NPs also mediated the specific delivery of Alexa-488-EV peptide to tumor tissue in vivo, provoking a high tumor growth retardation effect with minimal uptake by external organs and no toxic effects.
► LCC NP successfully mediates pH-sensitive release of attached EV therapeutic peptide.
► EV peptide in LCC NP treatment provoked a 40% reduction in H460 cell viability.
► LCC NPs showed high in vivo tumor specificity with no significant systemic toxicity.
► EV peptide in LCC NP treatment provoked massive H460 tumor growth retardation in vivo.
Journal: Cancer Letters - Volume 334, Issue 2, 1 July 2013, Pages 311–318